Comparison of the effect of different platelet GPIIb/IIIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography

Thrombosis Research

Volumn 104, Issue 1, 2001, Pages 49-56

  Mousa, Shaker A ^a   Forsythe, Mark S ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Abciximab; Aspirin; Binding kinetics; Clot strength and retraction; Endotoxin; Integrin; Orbofiban; Platelet aggregation; Platelet GPIIb IIIa antagonists; Roxifiban; Sibrafiban; Thrombin; Thromboelastography; Tissue factor; Xa

Indexed keywords

3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; ABCIXIMAB; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRIN; FIBRINOGEN RECEPTOR ANTAGONIST; LIPOPOLYSACCHARIDE; LOTRAFIBAN; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; THROMBOPLASTIN; UNCLASSIFIED DRUG; YZ 211;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FIBRIN CLOT; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY;

BIOMECHANICS; BLOOD COAGULATION; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; THROMBELASTOGRAPHY;

EID: 0035479217     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00336-X     Document Type: Article

References (29)

1. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death
2. Biochemical evidence of platelet activation in patients with persistent unstable angina
3. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications
4. Platelet membrane glycoprotein IIb/IIIa: Member of a family of RGD specific adhesion receptors
5. EPIC investigators: Randomized trial of coronary intervention with antibody against platelet GPIIb/IIIa integrin for reduction of clinical restenosis: Results at six months
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms
7. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, integrilin in elective coronary intervention
8. Profound inhibition of platelet aggregation with monoclonal antibody c7E3 after thrombolytic therapy: Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study
9. Ultrastructure of clots during isometric contraction
10. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface
11. Platelets interact with fibrin only after activation
12. Quantitative clot retraction: A method assessing the function of fresh and stored platelets and GPIIb/IIIa receptors
13. Novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP754: Receptor binding affinity and specificity
14. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists
15. Inhibition of platelet-mediated clot retraction by integrin antagonist
16. Blutgerinnungstudien mit der thromboelastograpie, einem ueuen untersuchungsverfahren
17. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass
18. Studies of fibrinolytic and coagulation factors during open heart surgery: II. Postoperative tendency and changes in the coagulation system
19. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies
20. Changes in transfusion therapy and re-exploration rate after institution of a blood management program in cardiac surgical patients
21. First chronic platelet glycoprotein IIb/IIIa integrin blockade: A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions
22. Profound and sustained inhibition of platelet aggregation by fradafiban, nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men
23. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in myocardial infarction
24. Lotrafiban: An oral platelet glycoprotein IIb/IIIa blocker
25. Novel antiplatelet therapies: Recent advances in the development of platelet GPIIb/IIIa receptor antagonists
26. Discovery of novel orally active non-peptide platelet GPIIb/IIIa receptor antagonist, DMP754: Comparative platelet binding profiles with c7E3
27. Orally active isoxazoline GPIIb/IIIa antagonists
28. Oral glycoprotein IIb/IIIa inhibition in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
29. Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thromboelastograph